How effective is crisaborole in the treatment of pediatric atopic dermatitis (AD)?

Updated: Apr 26, 2021
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
  • Print

Crisaborole, a phosphodiesterase-4 (PDE-4) inhibitor, is approved for children. In March 2020, the FDA expanded the indication to include infants and children aged 3 months or older. Use in pediatric patients aged 3 months to less than 2 years was supported by data from a 28-day open-label, safety, and pharmacokinetics trial (n=137). [32]   This boron-based PDE-4 inhibitor can be used in mild-to-moderate atopic dermatitis. [56] It reduces the dermatitis and associated pruritus without apparent undesirable side effects.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!